NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced that it will participate in the Planet MicroCap Las Vegas 2026 Conference scheduled for June 17-18, 2026. President and CEO Dave Rosa will attend the conference in Las Vegas, Nevada, where he is set to host one-on-one meetings with institutional investors and deliver a company presentation on Wednesday, June 17, 2026, at 12:00 p.m. Pacific Time.
The presentation, which will take place in TRACK 6 - Raphael 3, is expected to provide updates on the commercialization of the OneRF platform and anticipated milestones for the treatment of the brain, pain, and advanced drug delivery. Ahead of the conference, Mr. Rosa also participated in a CEO interview with Planet MicroCap host Robert Kraft, which can be viewed here.
NeuroOne has developed a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures while lowering costs and improving patient outcomes. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation.
The Planet MicroCap Conference provides a platform for emerging growth companies to connect with institutional investors. NeuroOne's participation highlights its ongoing efforts to advance its technology and expand its market presence. For more information about the conference or to schedule a meeting with management, visit the conference website here or contact the company's investor relations team.
NeuroOne's presentation is a key opportunity for investors to gain insights into the company's strategic direction and upcoming milestones. The OneRF platform, in particular, represents a significant advancement in the treatment of neurological disorders, offering both diagnostic and therapeutic capabilities. As the company continues to commercialize its products, its presentation at the conference could influence investor sentiment and market positioning.
Additional details about the presentation and the CEO interview can be accessed via the webcast link here. NeuroOne remains committed to transforming surgical care for neurological disorders through its innovative electrode technology and ongoing research initiatives.
